Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Mounjaro - A dual-hormone injection (GLP-1 and GIP) approved for weight loss
GIP enhances insulin secretion and plays a role in lipid metabolism
Saves muscle glycogen
Semaglutide 2.4 mg injection (Wegovy , Novo Nordisk ), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in June 2021 for chronic weight management in adults with overweight and 1 weight-related condition or obesity based on demonstrated weight reduction in clinical trials [10]
After injection, the medication enters the bloodstream and activates GLP-1 receptors throughout the body, signaling fullness to the brain's appetite centers and slowing gastric emptying
For a 10mg vial, 2mL of bac water produces a 5mg/mL solution
